AU2020403153A1 - Anti-serum albumin antibodies - Google Patents

Anti-serum albumin antibodies Download PDF

Info

Publication number
AU2020403153A1
AU2020403153A1 AU2020403153A AU2020403153A AU2020403153A1 AU 2020403153 A1 AU2020403153 A1 AU 2020403153A1 AU 2020403153 A AU2020403153 A AU 2020403153A AU 2020403153 A AU2020403153 A AU 2020403153A AU 2020403153 A1 AU2020403153 A1 AU 2020403153A1
Authority
AU
Australia
Prior art keywords
antigen
binding site
specific binding
certain embodiments
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020403153A
Other languages
English (en)
Inventor
Patrick A. Baeuerle
Nga Rewa HOUSTON
Bochong LI
Bradley M. LUNDE
Naveen MEHTA
Jennifer Michaelson
Bianka Prinz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cullinan Therapeutics Inc
Original Assignee
Cullinan Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullinan Oncology Inc filed Critical Cullinan Oncology Inc
Publication of AU2020403153A1 publication Critical patent/AU2020403153A1/en
Assigned to CULLINAN ONCOLOGY, INC. reassignment CULLINAN ONCOLOGY, INC. Amend patent request/document other than specification (104) Assignors: CULLINAN MANAGEMENT, INC.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020403153A 2019-12-11 2020-12-11 Anti-serum albumin antibodies Pending AU2020403153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946932P 2019-12-11 2019-12-11
US62/946,932 2019-12-11
PCT/US2020/064672 WO2021119531A1 (en) 2019-12-11 2020-12-11 Anti-serum albumin antibodies

Publications (1)

Publication Number Publication Date
AU2020403153A1 true AU2020403153A1 (en) 2022-06-30

Family

ID=76329090

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020403153A Pending AU2020403153A1 (en) 2019-12-11 2020-12-11 Anti-serum albumin antibodies

Country Status (8)

Country Link
US (1) US20230032087A1 (https=)
EP (1) EP4073114A4 (https=)
JP (1) JP7734132B2 (https=)
CN (1) CN115916816B (https=)
AU (1) AU2020403153A1 (https=)
CA (1) CA3161411A1 (https=)
IL (1) IL293780A (https=)
WO (1) WO2021119531A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293725A (en) 2019-12-11 2022-08-01 Cullinan Oncology Inc Anti-cd19 antibodies and multispecific binding proteins
US20250388663A1 (en) * 2022-08-17 2025-12-25 Institut National de la Santé et de la Recherche Médicale Improved anti-albumin nanobodies and their uses
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025201474A1 (zh) * 2024-03-28 2025-10-02 诺纳生物（苏州）有限公司 血清白蛋白结合蛋白及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
HRP20150175T1 (en) * 2005-12-16 2015-03-27 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
DK2211904T3 (en) * 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
AU2016330807B2 (en) * 2015-10-02 2023-08-10 F. Hoffmann-La Roche Ag Anti-human CD19 antibodies with high affinity
KR20180133442A (ko) * 2016-04-13 2018-12-14 비비아 바이오테크 에스.엘. 생체외 bite 활성화된 t 세포
WO2019077062A1 (en) * 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
JP7383704B2 (ja) * 2018-06-07 2023-11-20 カリナン オンコロジー インコーポレイテッド 多重特異性結合タンパク質およびその使用方法
US10815311B2 (en) * 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use

Also Published As

Publication number Publication date
CN115916816B (zh) 2026-02-17
EP4073114A4 (en) 2024-04-17
CN115916816A (zh) 2023-04-04
US20230032087A1 (en) 2023-02-02
CA3161411A1 (en) 2021-06-17
JP2023506834A (ja) 2023-02-20
JP7734132B2 (ja) 2025-09-04
WO2021119531A1 (en) 2021-06-17
EP4073114A1 (en) 2022-10-19
IL293780A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
US20250179181A1 (en) Multi-specific binding proteins and methods of use thereof
US12157771B2 (en) Proteins binding NKG2D, CD16 and CLEC12A
JP7844558B2 (ja) リンパ球における阻害経路の中和
JP7734132B2 (ja) 抗血清アルブミン抗体
US20200376034A1 (en) Antibody variable domains targeting cd33, and use thereof
CN111065649A (zh) 结合nkg2d、cd16和egfr、hla-e、ccr4或pd-l1的蛋白质
JP2020536543A (ja) 抗ｃｄ３８抗体および使用方法
US12428480B2 (en) Anti-CD19 antibodies and multi-specific binding proteins
EP3411403A1 (en) Bispecific t cell engaging antibody constructs
CN107001466A (zh) 对淋巴细胞中抑制途径的中和
US20250101107A1 (en) Cd8-targeted il-12 fusion proteins
EP4688863A1 (en) Methods of use of multi-specific binding proteins
HK40091232A (zh) 抗cd19抗体和多特异性结合蛋白

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CULLINAN ONCOLOGY, INC.

Free format text: FORMER NAME(S): CULLINAN MANAGEMENT, INC.